The global automated breast ultrasound systems (ABUS) market, valued at approximately US$ 1.95 billion in 2023, is projected to experience substantial growth, reaching an estimated US$ 7.23 billion by 2033. This expansion is driven by a robust compound annual growth rate (CAGR) of 14% over the forecast period.
Automated breast ultrasound systems have emerged as a crucial tool in breast cancer screening, offering enhanced imaging capabilities compared to traditional mammography, especially for patients with dense breast tissue. The increasing prevalence of breast cancer, combined with rising awareness of early detection and advancements in ultrasound technology, is fueling demand for ABUS worldwide.
As healthcare providers prioritize patient comfort, accuracy, and early cancer detection, automated breast ultrasound systems are gaining traction as a preferred screening option. The technology’s user-friendly interface and ability to generate 3D images provide radiologists with more detailed insights, which can lead to improved diagnostic accuracy and treatment outcomes.
ABUS offers several advantages over conventional methods, such as providing 3D images and reducing the dependency on operator expertise, leading to improved diagnostic accuracy and efficiency. Additionally, advancements in artificial intelligence and machine learning have further enhanced ABUS’s capabilities, enabling automated lesion detection and characterization.
The market has also been bolstered by the rising adoption of digital healthcare solutions and telemedicine, allowing for remote interpretation and consultation, thereby improving access to healthcare services for patients in remote areas. Moreover, increased investments in research and development have resulted in the launch of more sophisticated and user-friendly ABUS devices, encouraging their widespread adoption among healthcare providers.
However, challenges persist, such as the high cost of ABUS equipment, which may limit its accessibility in certain regions. Moreover, despite the benefits, there remains a need for continued education and training of medical professionals to ensure optimal utilization of ABUS technology.
Key Takeaways from FMI’s Automated Breast Ultrasound Systems Market Study:
- Increasing government investment to promote breast cancer awareness among women will bolster demand across the U.S.
- The U.K is expected to experience noteworthy growth as governments and private organizations aim at curbing high mortality rate due to breast cancer.
- Presence of modern healthcare infrastructure will increase automated breast ultrasound system adoption across Germany
- Saudi Arabia will offer lucrative opportunities owing to rapid urbanization and emergence of advance diagnostics centers.
- India is expected to exhibit increasing demand owing to increase in per capita income and to growing incidence of breast cancer among women.
- Hospitals are expected to lead the market driven by faster accessibility modern tool and availability of skilled professionals.
What are the Major Challenges Hindering the Automated Breast Ultrasound Systems Market?
A radiologist with expertise in ABUS is required to correctly interpret the volumetric 3D images and identify the region of the breast lesion. The lack of skilled radiologists and the increased cost of standardized training hamper the market growth.
Lack of awareness in emerging economies regarding breast cancer and underdeveloped healthcare infrastructure in underdeveloped countries are also hindering the market growth.
According to Winship Cancer Institute, breast ultrasound is more susceptible to producing false positives than mammography. The breast ultrasound system is also not equipped to indicate whether the tumor is benign or cancerous. The inability to display calcification among women above 45 years is a major concern among the market players.
Automated Breast Ultrasound Systems – Competitive Landscape
Key market players in the automated breast ultrasound system market are focusing on installing ABUS in hospitals and diagnostics centers to expand their global footprint. They are also working towards developing the accuracy of automated breast ultrasound systems for faster cancer screening assessment and getting government approval for their products.
Key players are investing heavily in research and development activities to develop essential and improved products. These players are adopting various market methodologies such as mergers, acquisitions, product launches, collaborations, and partnerships. They are distributing their products with local and international suppliers to reach relevant audiences to increase sales volume.
Other Essential Players in the Global Market are:
- GE Healthcare
- Hitachi Ltd
- SonoCine Inc
- Philips Healthcare
- Siemens Healthineers
- Supersonic Imagine
- Toshiba Corporation
- QT Ultrasound LLC
- Adaltis S.r.l.
- Volpara Health Technologies
- Delphinus Medical Technologies, Inc
- General Electric Company
- Hologic, Inc
- Telemed Systems, Inc
Recent Developments in the Global Market are:
- Hitachi being the global leader in smart life & eco-friendly systems launched its latest automated breast ultrasound system “SOFIA” capable of scanning and acquiring images of the complete breast.
- Koninklijke launched Philips EPIQ and Affiniti ultrasound systems as a part of its automated breast ultrasound system product range. Philips EPIQ is laced with an integrated eL18-4 transducer and employs anatomical intelligence for accurate imaging of the breast with high tissue density.
- Siemens Healthineers AG introduced a new automated breast ultrasound system “ACUSON S2000 ABVS” as a part of its imaging, diagnostics segment with a 3D imaging feature required to find the lesions in fatty and dense breast tissue.
Automated breast ultrasound system named “AWBUS” made by SonoCiné is capable of providing repeated scans of the whole breast with the same consistency and accuracy necessary for the accurate detection of cancer.
A Comprehensive Full Report
Automated Breast Ultrasound Systems Market by Category
By End User:
- Hospitals
- Diagnostic Imaging Laboratories
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube